Cancer stem cells and drug resistance: The potential of nanomedicine

Nanomedicine

Volumn 7, Issue 4, 2012, Pages 597-615

  Vinogradov, Serguei ^a   Wei, Xin ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

cancer microenvironment; cancer stem cells; drug efflux transporters; drug resistance; nanomedicine

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARBON NANOTUBE; CD34 ANTIGEN; CURCUMIN; DAUNORUBICIN; DEQUALINIUM; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYALURONIC ACID; HYPOXIA INDUCIBLE FACTOR; LIPOSOME; LONIDAMINE; MEPACRINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; NANOCAPSULE; NANOPARTICLE; NOTCH2 RECEPTOR; PACLITAXEL; PROTEIN BCL 2; RETINOIC ACID; SALINOMYCIN; SINGLE WALLED NANOTUBE; SONIC HEDGEHOG PROTEIN; TAMOXIFEN; TARIQUIDAR; TEMOZOLOMIDE; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; BINDING AFFINITY; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CANCER STEM CELL; CD34 SELECTION; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE TARGETING; HUMAN; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; METAPHASE; METASTASIS; MICELLE; NANOENCAPSULATION; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT; ULTRASOUND; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOMEDICINE; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 84859450097     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.22     Document Type: Review

References (70)

1. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 68, 4018-4021 (2008).
2. Dick JE. Looking ahead in cancer stem cell research. Nat. Biotechnol. 27(1), 44-46 (2009).
3. Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27(50), 6522-6537 (2008).
4. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 9(3), 307-319 (2009).
5. Rochat B. Importance of infux and effux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr. Cancer Drug Targets 9(5), 652-674 (2009).
6. Schatton T, Frank NY, Frank MH. Identifcation and targeting of cancer stem cells. Bioessays 31, 1038-1049 (2009).
7. Hong SP, Wen J, Bang S et al. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer 125, 2323-2331 (2009).
8. Ricci-Vitiani L, Pallini R, Biffoni M et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468(7325), 824-828 (2010).
9. Grange C, Tapparo M, Collino F et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung pre-metastatic niche. Cancer Res. 71(15), 5346-5356 (2011).
10. Liu T, Cheng W, Lai D, Huang Y, Guo L. Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep. 23(5), 1277-1284 (2010).
11. Shervington A, Lu C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 26(5), 535-542 (2008). (Pubitemid 351892589)
12. Nobili S, Landini I, Giglioni B et al. Pharmacological strategies for overcoming multidrug resistance. Curr. Drug Targets 7(7), 861-879 (2006).
13. Frank NY, Margaryan A, Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 65(10), 4320-4333 (2005). (Pubitemid 40775671)
14. Jin F, Zhao L, Guo YJ et al. Infuence of etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. Brain Res. 1336, 103-111 (2010).
15. Shigeta J, Katayama K, Mitsuhashi J et al. BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization. Cancer Sci. 101(8), 1813-1821 (2010).
16. Hu C, Li H, Li J et al. Analysis of ABCG2 expression and side population identifes intrinsic drug effux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29(12), 2289-2297 (2008).
17. Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 3, 237-246 (2008).
18. Honoki K, Fujii H, Kubo A et al. Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol. Rep. 24(2), 501-505 (2010).
19. Rausch V, Liu L, Kallifatidis G et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 70(12), 5004-5013 (2010).
20. + leukemic cells. Cancer Sci. 100(5), 948-955 (2009).
21. Teng Y, Wang X, Wang Y et al. Wnt/b-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 392(3), 373-379 (2010).
22. Deng YH, Pu XX, Huang MJ et al. 5-fuorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. Chin. J. Cancer 29(9), 810-815 (2010).
23. Wang Z, Li Y, Kong D et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69(6), 2400-2407 (2009).
24. Scadden DT. The stem-cell niche as an entity of action. Nature 441(7097), 1075-1079 (2006). (Pubitemid 43990719)
25. Folkins C, Man S, Xu P et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res. 67(8), 3560-3564 (2007). (Pubitemid 46762138)
26. Hovinga KE, Shimizu F, Wang R et al. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28(6), 1019-1029 (2010).
27. Williams RF, Sims TL, Tracey L et al. Maturation of tumor vasculature by interferon-b disrupts the vascular niche of glioma stem cells. Anticancer Res. 30(9), 3301-3308 (2010).
28. Morozevich GE, Kozlova NI, Ushakova NA, Preobrazhenskaia ME, Berman AE. Implication of integrin a5b 1 in human breast carcinoma apoptosis and drug resistance. Biomed. Khim. 57(1), 77-84 (2011).
29. Harada H, Kizaka-Kondoh S, Li G et al. Signifcance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26(54), 7508-7516 (2007). (Pubitemid 350207705)
30. Piret JP, Cosse JP, Ninane N et al. Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pat hw ay. Exp. Cell Res. 312(15), 2908-2920 (2006).
31. Wirthner R, Wrann S, Balamurugan K et al. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 a-defcient mouse embryonic fbroblasts. Carcinogenesis 29(12), 2306-2316 (2008).
32. Choi YJ, Rho JK, Lee SJ et al. HIF-1a modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines. J. Cancer Res. Clin. Oncol. 135(8), 1047-1053 (2009).
33. Schwartz DL, Bankson JA, Lemos R et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol. Cancer Ther. 9, 2057-2067 (2010).
34. Gupta PB, Onder TT, Jiang G et al. Identifcation of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138(4), 645-659 (2009).
35. Mimeault M, Batra SK. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Clin. Med. 6, 31 (2011).
36. Lim KJ, Bisht S, Bar EE et al. A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biol. Ther. 11(5), 464-473 (2011).
37. Banzato A, Bobisse S, Rondina M et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin. Cancer Res. 14(11), 3598-3606 (2008).
38. Choi KY, Chung H, Min KH et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 31(1), 106-114 (2010).
39. Upadhyay KK, Bhatt AN, Mishra AK et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(g-benzyl L-glutamate)-b- hyaluronan polymersomes. Biomaterials 31(10), 2882-2892 (2010).
40. Wu W, Shen J, Banerjee P et al. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. Biomaterials 31(29), 7555-7566 (2010).
41. Wu W, Shen J, Banerjee P, Zhou S. Water-dispersible multifunctional hybrid nanogels for combined curcumin and photothermal therapy. Biomaterials 32(2), 598-609 (2011).
42. Bourseau-Guilmain E, Bejaud J, Griveau A et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int. J. Pharm. 423(1), 93-101 (2011).
43. Zhou P, Hatziieremia S, Elliott MA et al. Uptake of synthetic low density lipoprotein by leukemic stem cells-a potential stem cell targeted drug delivery strategy. J. Control. Release 148(3), 380-387 (2010).
44. Li RJ, Ying X, Zhang Y et al. All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J. Control. Release 149 (3), 281-291 (2011).
45. Guo J, Zhou J, Ying X et al. Effects of stealth liposomal daunorubicin plus tamoxifen on the breast cancer and cancer stem cells. J. Pharm. Pharm. Sci. 13(2), 136-151 (2010).
46. Zhang L, Yao HJ, Yu Y et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials 33(2), 565-582 (2012).
47. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol. Pharm. 8(1), 185-203 (2011).
48. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136(1), 21-29 (2009).
49. Lei T, Srinivasan S, Tang Y et al. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine 7(3), 324-332 (2011).
50. Mamaeva V, Rosenholm JM, Bate-Eya LT et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol. Ther. 19(8), 1538-1546 (2011).
51. Kim TH, Mount CW, Gombotz WR et al. The delivery of doxorubicin to 3-D multicellular spheroids and tumors in a murine xenograft model using tumor-penetrating triblock polymeric micelles. Biomaterials 31(28), 7386-7397 (2010).
52. Yao HJ, Ju RJ, Wang XX et al. The anti-tumor effcacy of functional paclitaxel nanomicelles in treating resistant breast cancers by oral delivery. Biomaterials 32(12), 3285-3302 (2011).
53. Pan X, Thompson R, Meng X et al. Tumor-targeted RNA-interference: functional non-viral nanovectors. Am. J. Cancer Res. 1(1), 25-42 (2011).
54. Patil YB, Swaminathan SK, Sadhukha T et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2), 358-365 (2010).
55. Liu C, Zhao G, Liu J et al. Novel biodegradable lipid nano complex for siRNA delivery signifcantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J. Control. Release 140 (3), 277-283 (2009).
56. Chen Y, Bathula SR, Li J et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 285(29), 22639-22650 (2010).
57. Verma A, Guha S, Diagaradjane P et al. Therapeutic signifcance of elevated tissue transglutaminase expression in pancreatic cancer. Clin. Cancer Res. 14(8), 2476-2483 (2008). (Pubitemid 351551083)
58. Kato T, Natsume A, Toda H et al. Effcient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17(11), 1363-1371 (2010).
59. Zhang H, Gerson T, Varney ML et al. Multifunctional peptide-PEG intercalating conjugates: programmatic of gene delivery to the blood-brain barrier. Pharm. Res. 27(12), 2528-2543 (2010).
60. Glazer ES, Zhu C, Massey KL et al. Noninvasive radiofrequency feld destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin. Cancer Res. 16(23), 5712-5721 (2010).
61. Khdair A, Chen D, Patil Y et al. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. J. Control. Release 141(2), 137-144 (2010).
62. Barth BM, Altlnoglu EI, Shanmugavelandy SS et al. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 5(7), 5325-5337 (2011).
63. Wang CH, Chiou SH, Chou CP et al. Photothermolysis of glioblastoma stem-like cells targeted by carbon nanotubes conjugated with CD133 monoclonal antibody. Nanomedicine 7(1), 69-79 (2011).
64. Li R, Wu R, Zhao L et al. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. ACS Nano 4(3), 1399-1408 (2010).
65. Grainger SJ, Serna JV, Sunny S et al. Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol. Pharm. 7(6), 2006-2019 (2010).
66. Bae YH, Park K. Targeted drug delivery to tumors: myth, reality and possibility. J. Control. Release 153(3), 198-205 (2011).
67. Milane L, Ganesh S, Shah S et al. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 155(2), 237-247 (2011).
68. Galmarini CM, Warren G, Senanayake MT, Vinogradov SV. Effcient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int. J. Pharm. 395(1-2), 281-289 (2010)
69. Ambardekar V V, Han HY, Varney ML et al. The modifcation of siRNA with 3́ cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes. Biomaterials 32(5), 1404-1411 (2011).
70. Senanayake TM, Warren G, Vinogradov SV. Novel anticancer polymeric conjugates of activated nucleoside analogs. Bioconjug. Chem. 22(10), 1983-1993 (2011).